Duration of the effects of intravenous alendronate in postmenopausal women and in patients with primary hyperparathyroidism and Paget's disease of bone

The Influence of Alendronate on Bone Formation and Resorption in a Rat Ectopic Bone Development Model

“…21 In addition, studies performed on bone cell cultures, using very low concentrations of bisphosphonates, 23,24 found increased parameters for bone formation. It was previously suggested that alendronate treatment of osteoporotic patients increased bone mass, 16 and pamidronate has similar effects. 25 Although there are several hypotheses to explain the increase in bone mass resulting from inhibitors of bone resorption, most of these hypotheses propose an indirect effect.…”

“…inhibits bone loss. [10][11][12][13]16,17,22,24,25,28 It is of interest that alendronate maintained the normal characteristics of hematopoietic bone marrow during the entire experiment in contrast to the non-treated animals.…”

“…[10][11][12] Their biological effects are attributed mainly to their incorporation in bone, enabling direct interaction with osteoclasts and osteoblasts through a variety of biochemical pathways. [13][14][15] While their effect on reducing bone resorption is well documented, 16,17 their effect on bone formation is still uncertain.…”

Paget’s disease

“…Alendronate at a dosage of 40 mg/die for 6 months has proven efficacious in reducing disease activity and improving the radiographic picture both in studies comparing it against etidronate and in non-controlled studies (87)(88)(89)(90). Alendronate is not available in Italy in the formulation approved for the treatment of Paget's disease.…”

Comparison of the Effects of Local Application of Hydroxyapatite Graft Soaked with Alendronate Solution and Pure Hydroxyapatite Graft in the Mandible of Ovariectomized Rats

“…An example of such bone metabolism mediators are the bisphosphonates, a group of carbon-substituted pyrophosphate analogs, which are effective bone resorption inhibitors. they have been effectively applied in the control of osteolysis or reduction of systemic bone loss in Paget's disease, metastatic bone disease, hypercalcemia of malignancy (1), and osteoporosis (25). Bisphosphonates bind strongly to apatite crystals, mainly on remodeling surfaces and inhibit their growth, aggregation and dissolution (19,24,26,34).…”